Home › Funds › Boussard & Gavaudan Investment Management LLP › BBIO

Boussard & Gavaudan Investment Management LLP position in BBIO

BRIDGEBIO PHARMA INC · Health Care

Boussard & Gavaudan Investment Management LLP reported holding 26,000 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q1 2026 13F filing — a position valued at US$46.2M, representing 5.07% of its reported portfolio and ranking #6 among its reported holdings. Boussard & Gavaudan Investment Management LLP first reported this position in Q1 2026.

Latest position (Q1 2026)26.00K sh
Reported value held$46.24M
Portfolio Weight5.07%
First reportedQ1 2026
Last changeNew
Updated2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

How Boussard & Gavaudan Investment Management LLP's BBIO position evolved

Boussard & Gavaudan Investment Management LLP first disclosed a stake in BBIO in Q1 2026 at 26,000 shares (US$46.2M).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 26.00K $46.24M New

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 48 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has Boussard & Gavaudan Investment Management LLP held BBIO?

Boussard & Gavaudan Investment Management LLP has disclosed BBIO holdings in 1 of the last 1 reported quarters, going back to Q1 2026.

What is Boussard & Gavaudan Investment Management LLP's current position in BBIO?

As of Q1 2026, Boussard & Gavaudan Investment Management LLP holds 26.00K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $46.24M, representing 5.07% of its reported portfolio and ranking #6.

Has Boussard & Gavaudan Investment Management LLP been buying or selling BBIO?

In the latest 13F filing (Q1 2026), Boussard & Gavaudan Investment Management LLP newly opened its position in BBIO.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.